Imaging SV2A in Mood Disorders

This non-randomised, parallel basic-science study compares SV2A availability across individuals with MDD, PTSD, bipolar disorder and healthy controls using PET (APP311/SDM-8/SynVesT-1).

A subset of participants undergo ketamine administration between scans to test whether ketamine increases SV2A density; imaging is combined with cognitive testing and physiological monitoring.

Outcomes include regional SV2A availability pre- and post-ketamine, correlations with antidepressant response, and examination of group and gender differences.